Skip to main content
ASND logo

ASND

Ascendis Pharma A/S

$270.32

0.32%

Trade Ideas Performance

Latest Closed Trade Idea

$270.32

0.32%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

4

Social

16

About

Events of Ascendis Pharma A/S (ASND)

Over the past six months, Ascendis Pharma's stock was impacted by several events: in August 2026, the company reported quarterly earnings, missing EPS estimates but exceeding revenue estimates, leading to a 3.6% stock decline. A director purchased 2,000 shares for $492,660.00. In November 2026, Wall Street Zen upgraded the stock to a 'buy' rating, and analysts maintained an average 'Moderate Buy' rating with a target price of $305.95. In October 2026, positive five-year clinical trial results for TransCon PTH (YORVIPATH) and a positive CHMP opinion for TransCon CNP led to a 3.60% rise in ASND stock. The company also announced a planned $400 million share repurchase program and regained rights to its TransCon technology in metabolic and cardiovascular diseases. Additionally, an SVP reported an insider sell of 3,000 shares, and a patent dispute over the achondroplasia drug Yuviwel was settled.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)